Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | F2 | P00734 | 3/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.49 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.49 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.49 |
| ▸ | HTR6 | P50406 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SCN1A | P35498 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10883679 | 0.81 | CA1 (0.61) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL9639733 | 0.78 | CA1 (0.63) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL9639738 | 0.78 | CA1 (0.63) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL28463 | 0.78 | CA1 (0.63) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL547461 | 0.78 | CA1 (0.68) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL3071825 | 0.78 | CA1 (0.68) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL29965319 | 0.78 | CA1 (0.68) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL4079218 | 0.77 | CA1 (0.52) | CA1CA2CA9F2PRSS1 | |
| SCHEMBL30583821 | 0.77 | CA1 (0.52) | CA1CA2CA9F2PRSS1 | |
| Water SCHEMBL4291375 | 0.77 | CA1 (0.61) | CA1CA2CA9F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1167366-B1 | AMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-6562849-B1 | Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. | SANKYO COMPANY, LIMITED (JP) | 2003-05-13 | — | — | US | disclosed |
| US-20030078426-A1 | Amine derivative compounds | SANKYO COMPANY, LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| US-6342606-B2 | REACTING PYRIDINE ESTER DERIVATIVE WITH A REDUCING AGENT, AN ALKYLATING AGENT, AN ALKENYLATING AGENT, AN ARYLATING AGENT OR AN ARALKYLATING AGENT TO OBTAIN A PYRIDINE CARBONYL DERIVATIVE, REDUCING | KURARAY CO., LTD. (JP) | 2002-01-29 | — | — | US | disclosed |
| EP-1167366-A1 | AMINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-20010031871-A1 | Method for producing pyridine derivatives | KURARAY CO., LTD. (JP) | 2001-10-18 | — | — | US | disclosed |
| US-6265580-B1 | REACTING AMINE DERIVATIVE WITH CARBONYLATING AGENT AND NITRILE DERIVATIVE | KURARAY CO., LTD. (JP) | 2001-07-24 | — | — | US | disclosed |
| US-6111111-A | Intermediates for producing pyridine derivatives | KURARAY CO., LTD. (JP) | 2000-08-29 | — | — | US | disclosed |
| EP-0911335-A2 | Method for producing furopyridine derivatives and intermediate compounds | KURARAY CO., LTD. (JP) | 1999-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031871-A1 | Method for producing pyridine derivatives | CYP2E1, CBR1, CBR3 | CA1 662/4885CA2 537/4885CA9 816/4885 |
| US-20030078426-A1 | Amine derivative compounds | H1-10, APOB, PRMT1 | CA1 2629/4885CA2 1149/4885CA9 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.